Study S001370

A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of HRS-7535 in Adults With Diabetic Kidney Disease in Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT06415214
Acronym: SOLID-DKD
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 281
Start: 2024-06-21
Primary completion: 2025-07-15
Lead sponsor: Shandong Suncadia Medicine Co., Ltd.
Conditions: Diabetic Kidney Disease, Type 2 Diabetes
Interventions: DRUG:Placebo; DRUG:HRS-7535
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Ratio of UACR at week 16 to UACR at baseline [at Week 16]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0004355	Efficacy and safety of HRS-7535, an oral small-molecule GLP-1 receptor agonist, in patients with diabetic kidney disease (SOLID-DKD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lv R, EClinicalMedicine	2026	Randomized trial	PMID 42472282 DOI	cites ClinicalTrials.gov:NCT06415214; registry reference DERIVED:42472282
R0045356	Efficacy and Safety of the Oral Small-Molecule GLP-1 Receptor Agonist HRS-7535 in Patients with Diabetic Kidney Disease Xiaoying Du, Journal of the American Society of Nephrology	2025	Randomized trial	DOI	cites ClinicalTrials.gov:NCT06415214